Elevation of anti-cytokeratin 19 antibody in sera of the patients with idiopathic pulmonary fibrosis and pulmonary fibrosis associated with collagen vascular disorders

It has been suggested that cytokeratin 19 is expressed in regenerated bronchoepithelial cells in patients with pulmonary fibrosis, and serum cytokeratin 19 fragment is elevated in patients with pulmonary fibrosis. We hypothesized that serum antibodies to cytokeratin 19 may be formed in patients with...

Full description

Saved in:
Bibliographic Details
Published in:Lung 1999-09, Vol.177 (5), p.311-319
Main Authors: Fujita, J, Dobashi, N, Ohtsuki, Y, Yamadori, I, Yoshinouchi, T, Kamei, T, Tokuda, M, Hojo, S, Okada, H, Takahara, J
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Arthritis, Rheumatoid - diagnosis
Arthritis, Rheumatoid - immunology
Autoantibodies - blood
Blotting, Western
Collagen Diseases - diagnosis
Collagen Diseases - immunology
Dermatomyositis - diagnosis
Dermatomyositis - immunology
Enzyme-Linked Immunosorbent Assay
Female
Humans
Immunoenzyme Techniques
Keratins - immunology
Male
Middle Aged
Pulmonary Fibrosis - diagnosis
Pulmonary Fibrosis - immunology
Sjogren's Syndrome - diagnosis
Sjogren's Syndrome - immunology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:It has been suggested that cytokeratin 19 is expressed in regenerated bronchoepithelial cells in patients with pulmonary fibrosis, and serum cytokeratin 19 fragment is elevated in patients with pulmonary fibrosis. We hypothesized that serum antibodies to cytokeratin 19 may be formed in patients with pulmonary fibrosis. To prove the existence of anti-cytokeratin 19 antibodies in patients' sera, human recombinant cytokeratin 19 was stained with patients' sera by a Western immunoblot. Then, we tried to establish an enzyme-linked immunosorbent assay to quantitate anti-cytokeratin 19 antibody in the sera of patients with idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis associated with collagen vascular disorders (PF-CVD). We demonstrated the anti-cytokeratin 19 antibody in patient' sera by a Western immunoblot. In patients with IPF and PF-CVD, significantly high anti-cytokeratin 19 antibody was demonstrated compared with normal volunteers, patients with chronic bronchitis, and patients with pneumonia. These results suggest that anti-cytokeratin 19 antibody may have played a role in the process of lung injury in pulmonary fibrosis.
ISSN:0341-2040
1432-1750
DOI:10.1007/PL00007649